Sensitization of Human Cancer Cells to Gemcitabine by the Chk1 Inhibitor MK-8776: Cell Cycle Perturbation and Impact of Administration Schedule in Vitro and in Vivo

Authors

Ryan Montano, Dartmouth College
Ruth Thompson, Dartmouth College
Injae Chung, Duksung Women's UniversityFollow
Huagang Hou, Dartmouth College
Nadeem Khan, Dartmouth College
Alan Eastman, Dartmouth CollegeFollow

Document Type

Article

Publication Date

12-21-2013

Publication Title

BioMed Central Cancer

Department

Geisel School of Medicine

Abstract

Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea. Here, we address the importance of appropriate drug scheduling when gemcitabine is combined with the Chk1 inhibitor MK-8776, and the mechanisms involved in the schedule dependence.

DOI

10.1186/1471-2407-13-604

Original Citation

Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer. 2013 Dec 21;13:604. doi: 10.1186/1471-2407-13-604. PMID: 24359526; PMCID: PMC3878047.

Dartmouth Digital Commons Citation

Montano, Ryan; Thompson, Ruth; Chung, Injae; Hou, Huagang; Khan, Nadeem; and Eastman, Alan, "Sensitization of Human Cancer Cells to Gemcitabine by the Chk1 Inhibitor MK-8776: Cell Cycle Perturbation and Impact of Administration Schedule in Vitro and in Vivo" (2013). Dartmouth Scholarship. 578.
https://digitalcommons.dartmouth.edu/facoa/578